Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 2013

View Archived Issues

Epizyme to develop companion diagnostics for two novel HMT inhibitors

New software application for personalized medicine presented

Listeria-based prostate cancer vaccines developed at Aduro BioTech

Glytech designs novel cancer immunotherapeutic

Maruishi Pharmaceutical and Cara Therapeutics sign license agreement for CR-845

UCB updates pipeline progress of first quarter 2013

Humanized anti-cocaine MAb demonstrates in vivo efficacy

Angion Biomedica presents CYP17 inhibitors for the treatment of prostate cancer

AstraZeneca reports activities of first quarter 2013

MorphoSys begins phase II MOR-208 trial

Phase II results presented for solithromycin in the treatment of urogenital gonorrhea

Novel selective PI3K-beta isoform inhibitors show promising oncolytic properties

Merck & Co. discloses new JAK inhibitors

GlaxoSmithKline prepares novel fatty acid synthase inhibitors

Novartis synthesizes new histamine H3 receptor antagonists/agonists

Alimera Sciences launches Iluvien in the U.K.

Merck & Co. and Pfizer to develop and commercialize ertugliflozin

Gilead receives FDA complete response letters for elvitegravir and cobicistat

Nuvilex to advance Cell-in-a-Box technology to phase III

Addex's GABA(B) receptor PAM reduces alcohol intake in preclinical model

FDA accepts for review Octapharma's BLA for investigational 4-factor PCC octaplex

Theravance board of directors approves plan to split into two publicly traded companies

Impax Pharmaceuticals and GSK terminate IPX-066 collaboration

Veloxis Pharmaceuticals submits MAA to EMA for LCP-Tacro

Novartis initiates phase II trial of INC-280 triggering milestone payment to Incyte

SD-101 receives FDA breakthrough therapy designation for epidermolysis bullosa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...